MTOR inhibition in breast cancer: Unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 7, 2011, Pages 859-872

  O'Regan, Ruth ^a   Hawk, Natalyn Nicole ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; everolimus; mTOR inhibitors; ridaforolimus; temsirolimus

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BEVACIZUMAB; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; FULVESTRANT; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; COMBINATION CHEMOTHERAPY; CONFUSION; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INFECTION; KIDNEY CARCINOMA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79958257007     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.575362     Document Type: Review

References (92)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe. Eur J Cancer 2010;46:765-81
3. Perez-Tenorio G, Stal O; Southeast Sweden Breast Cancer Group. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5 (Pubitemid 34185089)
4. Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy. FEBS Lett 2010;584:1287-95
5. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84
6. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20 (Pubitemid 46095391)
7. Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995;270:50-1
8. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-50 (Pubitemid 35204715)
9. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804:43-9
10. Wu GJ, Sinclair CS, Paape J, et al. 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGMA1B genes. Cancer Res 2000;60:5371-5
11. Barlund M, Forozan F, Kononen J, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000;92:1252-9 (Pubitemid 30627733)
12. Koziczak M, Hynes NE. Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 2004;279:50004-11 (Pubitemid 39577810)
13. Zhao JJ, Liu Z, Wang L, et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Nat Acad Sci USA 2005;102:18443-8 (Pubitemid 43011245)
14. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Nat Acad Sci USA 2005;102:802-7 (Pubitemid 40282746)
15. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5 (Pubitemid 41351083)
16. Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 2001;61:5985-91 (Pubitemid 32762525)
17. Feilotter HE, Coulon V, McVeigh JL, et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 1999;79:718-23 (Pubitemid 29082095)
18. Rhei E, Kang L, Bogomolniy F, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997;57:3657-9 (Pubitemid 27381202)
19. Garcia JM, Silva J, Pena C, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004;41:117-24 (Pubitemid 39096737)
20. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155:1253-60 (Pubitemid 29488932)
21. Tsutsui S, Inoue H, Yasuda K, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005;68:398-404 (Pubitemid 41160970)
22. deGraffenried LA, Fulcher L, Friedrichs WE, et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004 15: 1510-16 (Pubitemid 39409742)
23. Jiang WG, Sampson J, Martin TA, et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005;41:1628-36 (Pubitemid 40981846)
24. Sato T, Nakashima A, Guo L, et al. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010;29:2746-52
25. Carraway H, Hidalgo M. New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004;6:219-24
26. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-88 (Pubitemid 36403572)
27. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-41
28. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-Kinase/AKT-mediated activation of estrogen receptor alpha. J Biol Chem 2001;276:9817-24
29. Beeram M, Tan QT, Tekmal RR, et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007;18:1323-8 (Pubitemid 47305004)
30. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-28 (Pubitemid 41003721)
31. Ghayad SE, Bieche I, Vendrell JA, et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 2008;99:1992-2003
32. Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA. Rsk2 allosterically activates estrogen receptor a by docking to the hormone-binding domain. EMBO J 2005;20:3484-94 (Pubitemid 32634355)
33. Generali D, Fox SB, Brizzi MP, et al. Down-regulation of phosphatidylinositol 3-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008;14:2673-80
34. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003;22:3205-12 (Pubitemid 36712932)
35. Tang CK, Perez C, Grunt T, et al. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 1996;56:3350-8 (Pubitemid 26242988)
36. Aronica SM, Katzenellenbogen BS. Progesterone receptor regulation in uterine cells:stimulation by estrogen, cyclic adenosine 3,5-monophosphate, and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology 1991;128:2045-52
37. Furstenau DK, Mitra N, Wan F, et al. Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ. Breast Cancer Res Treat 2010 [Epub ahead of print; doi: 10.1007/s10549-010-1227-y]
38. Mendoza RA, Enriquez MI, Mejia SM, et al. Interactions between IGF-I, estrogen receptor-alpha (ERalpha), and ERbeta in regulating growth/apoptosis of MCF-7 human breast cancer cells. J Endocrinol 2011;208:1-9
39. Campbell CI, Petrik JJ, Moorehead RA. ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis. Mol Cancer 2010;9:235
40. Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 2010 [Epub ahead of print; doi: 10.1158/1078-0432.CCR-10-1903]
41. Kim JH, Cho YH, Park YL, et al. Prognostic significance of insulin growth factor-I receptor and insulin growth factor binding protein-3 expression in primary breast cancer. Oncol Rep 2010;23:989-95
42. Bartucci M, Morelli C, Mauro L, et al. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001;61:6747-54 (Pubitemid 32896497)
43. Zatelli MC, Minoia M, Mole D, et al. Growth hormone excess promotes breast cancer chemoresistance. J Clin Endocrinol Metab 2009;94:3931-8
44. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35 (Pubitemid 34155123)
45. Afinitor (everolimus) [prescribing information]. Novartis Pharmaceuticals Corp., East Hanover, NJ; 2009
46. Torisel (temsirolimus) [prescribing information]. Wyeth Pharmaceuticals Inc., Philadelphia PA; 2010
47. Sessa C, Tosi D, Vigano L, et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol 2010;21:1315-22
48. O'Regan R, Andre F, Campone M, et al. RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-over expressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial [abstract 3119]. San Antonio Breast Cancer Symposium; 10 - 14 December 2008
49. Cardoso F, Gianni L, Jerusalem G, et al. Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab [abstract 5004]. Eur J Cancer Suppl 2009;7:261
50. Cardoso F, Campone M, Massacesi C, et al. Everolimus (Afinitor), trastuzumab (H), and paclitaxel (P) or vinorelbine (V) in the treatment of HER-2+ metastatic breast cancer (MBC) patients (pts) pre-treated with lapatinib-containing therapy: pooled analysis of 2 phase I studies [abstract 5064]. San Antonio Breast Cancer Symposium; 9 - 13 December 2009
51. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008;44:84-91 (Pubitemid 350256937)
52. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
53. Chow L, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006;100(Suppl 1):6091
54. Macaskill EJ, Bartlett JM, Sabine VS, et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat 2010 [Epub ahead of print; doi: 10.1007/s10549-010-0967-z]
55. Sabine VS, Sims AH, Macaskill EJ, et al. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat 2010;122:419-28
56. Vanderbilt-Ingram Cancer Center. Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer. ClinicalTrials.gov NCT00930930. Available from: http://clinicaltrials.gov/ct2/ show/NCT00930930? term=NCT00930930&rank=1
57. von Minckwitz G, Bauerfeind I, Gerber B, et al. Geparquinto: First planned safety analysis on 60 patients with HER2 negative primary breast cancer receiving neoadjuvant chemotherapy bevacizumab or RAD001 (GBG 44) [abstract 1096]. San Antonio Breast Cancer Symposium; 9 - 13 December 2009
58. Ellard SL, Clemons M, Gelmon KA, et al. Randomized Phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009;27:4536-41
59. Mayer I, Burris H, Bendell J, et al. A phase I trial of weekly cisplatin, paclitaxel and RAD001, an mTOR inhibitor, in patients with HER2-negative metastatic breast cancer [abstract 250]. ASCO Breast Cancer Symposium; 8 - 10 October 2009
60. Vanderbilt-Ingram Cancer Center. Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer. ClinicalTrials.gov NCT01031446. Available from: http://clinicaltrials.gov/ct2/show/NCT01031446? term=NCT01031446& rank=1
61. Novartis Pharmaceuticals. Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer ClinicalTrials.gov NCT00426556. Available from: http://clinicaltrials. gov/ct2/show/NCT00426556?term=NCT00426556& rank=1
62. Novartis Pharmaceuticals. Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer. ClinicalTrials. gov NCT00426530. Available from: http://clinicaltrials.gov/ct2/show/NCT00426530? term=NCT00426530&rank=1
63. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47 (Pubitemid 41115390)
64. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314-22 (Pubitemid 46206985)
65. Baselga J, Roche H, Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study [abstract 1068]. Breast Cancer Res Treat 2005;94(Suppl 1):S62
66. Novartis Pharmaceuticals. Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer. ClinicalTrials.gov NCT01007942. Available from: http://clinicaltrials.gov/ct2/show/NCT01007942?term=NCT01007942& rank=1
67. Hartford CM, Desai AA, Janisch L, et al. A Phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009;15:1428-34
68. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-7 (Pubitemid 351171685)
69. Merck. Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009). ClinicalTrials.gov NCT00736970. Available from: http://clinicaltrials.gov/ct2/show/NCT00736970? term=NCT00736970&rank=1
70. Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007;117:730-8 (Pubitemid 46348531)
71. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213-23 (Pubitemid 38988774)
72. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004;14:1650-6 (Pubitemid 39239362)
73. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74
74. Veilleux A, Houde VP, Bellmann K, Marette A. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol Endocrinol 2010;24:766-78
75. Evangelisti C, Ricci F, Tazzari P, et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011 [Epub ahead of print; doi: 10.1038/leu.2011.20]
76. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68:9221-30
77. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30
78. Liu L, Greger J, Shi H, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009;69:6871-8
79. Novartis Pharmaceuticals. A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer. ClinicalTrials.gov NCT00620594. Available from: http://clinicaltrials.gov/ct2/ show/NCT00620594?term=NCT00620594& rank=1
80. Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008;321:1499-502
81. Federation Nationale des Centres de Lutte Contre le Cancer. Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery ClinicalTrials. gov NCT00674414. Available from: http://clinicaltrials.gov/ct2/show/NCT00674414?term=NCT00674414& rank=1
82. M.D. Anderson Cancer Center. Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer ClinicalTrials.gov. NCT00499603. Available from: http://clinicaltrials.gov/ct2/show/NCT00499603? term=NCT00499603&rank=1
83. Organisation for Oncology and Translational Research. Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy. ClinicalTrials.gov. NCT01088893. Available from: http://clinicaltrials.gov/ct2/show/NCT01088893? term= NCT01088893&rank=1
84. German Breast Group. A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer. ClinicalTrials.gov NCT00567554. Available from: http://clinicaltrials.gov/ct2/show/NCT00567554?term= NCT00567554& rank=1
85. Cancer Institute of New Jersey. Weekly Abraxane (Paclitaxel Albumin-Stabilized Nanoparticle Formulation) and RAD001 (Everolimus) in Women With Locally Advanced or Metastatic Breast Cancer: A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG). ClinicalTrials.gov NCT00934895. Available from: http://clinicaltrials.gov/ct2/show/NCT00934895? term=NCT00934895&rank=1
86. Penn State University. Trial of RAD001 in Triple Negative Metastatic Breast Cancer. ClinicalTrials.gov NCT00827567. Available from: http://clinicaltrials.gov/ct2/show/NCT00827567?term=NCT00827567& rank=1
87. Sarah Cannon Research Institute. Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer. ClinicalTrials. gov NCT00915603. Available from: http://clinicaltrials.gov/ct2/ show/NCT00915603?term=NCT00915603& rank=1
88. Emory University. Trastuzumab With or Without Everolimus in Estrogen Receptor-Positive Metastatic Breast Cancer ClinicalTrials.gov NCT00912340. Available from: http://clinicaltrials.gov/ct2/show/NCT00912340?term= NCT00912340& rank=1
89. University of Kentucky. Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure. ClinicalTrials.gov NCT00570921. Available from: http://clinicaltrials.gov/ct2/ show/NCT00570921?term= NCT00570921&rank=1
90. German Breast Group. Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases (RADAR). ClinicalTrials.gov NCT00466102. Available from: http://clinicaltrials.gov/ct2/show/NCT00466102?term= NCT00466102&rank=1
91. Novartis Pharmaceuticals. Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer. ClinicalTrials. gov NCT00876395. Available from: http://clinicaltrials.gov/ct2/show/NCT00876395?term=NCT00876395& rank=1
92. Novartis Pharmaceuticals. Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole. ClinicalTrials.gov NCT00863655. Available from: http://clinicaltrials.gov/ct2/show/NCT00863655?term=NCT00863655& rank=1